Tag Archive for: BioNTech

BioNTech is making moves in early 2024 to strengthen its CAR T pipeline, with a $250 million licensing and manufacturing deal announced Thursday with Autolus Therapeutics to advance the companies’ respective programs.

BioNTech and its partner Duality Biologics said they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca, and Daiichi Sankyo.

Today the company said it expects to return to revenue growth in 2025 when the ongoing decline in its COVID-19 vaccine business would bottom out, and that it would invest to scale up its oncology business thereafter.

A German court invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, in a blow to CureVac’s claims for a share in billions of euros in COVID-19 vaccine revenues.

The European Patent Office declared a contested mRNA patent owned by Moderna invalid on Tuesday, the office said, handing a win to BioNTech and its partner Pfizer in a patent dispute between the two coronavirus vaccine makers.

Several cancer vaccine candidates are flying through clinical trials with promising results. Unlike traditional vaccines that aim to prevent a disease from occurring, therapeutic cancer vaccines train the patient’s immune system, enabling T cells to patrol the body for cancer cells and destroy them.

Looking beyond the coronavirus business, the company has renewed its focus on a growing development pipeline in oncology, which includes use of the mRNA technology pioneered in the vaccine as well as precision anti-cancer drugs from a class known as antibody-drug conjugates and therapies based on modified immune cells.

“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine research and development, said in a statement.

MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets, and BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.

Pfizer, BioNTech, and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome’s lawsuit accusing the COVID-19 vaccine makers of infringing a patent related to messenger RNA technology.